Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

COMPACT

16 evidence topics · 5 sources

Objective
Location and study date
Trial locations and global end date
FieldReported value
Planned region“Argentina”
Planned region“Australia”
Planned region“Canada”
Planned region“European Union”
Planned region“United States”
Global end of trial“2015-10-12”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack frequency as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Actual randomization
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline age
CharacteristicReported value
Median age, years (range)“40 (12 to 72)”
Efficacy results
Monthly attack-rate differences versus placebo
RegimenMean difference, attacks per month
40 IU/kg twice weekly“-2.42”View highlighted excerpt for this quote
60 IU/kg twice weekly“-3.51”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The crossover trial randomized 90 participants against a planned enrollment of 100, and 79 participants completed it. Each participant received active treatment and placebo in sequence, and efficacy was evaluated “for the last 14 weeks of each treatment period” of the 32-week study, so period and carryover effects can influence the estimates. The efficacy results reported for this trial are mean differences from placebo in monthly attack rate (-2.42 attacks per month with 40 IU/kg and -3.51 with 60 IU/kg twice weekly), which are not directly comparable with absolute attack rates reported for parallel-group designs. No health-related quality of life result for this trial was identified. The trial enrolled participants aged 12 years or older, with a median age of 40 years (range, 12 to 72). Subcutaneous C1 inhibitor was compared with placebo only, so comparison with other prophylactic agents relies on cross-trial comparison.